Skip to main content

Farnesyl Protein Transferase Inhibition: A Novel Approach to Anti-tumor

Buy Article:

$63.00 plus tax (Refund Policy)

Farnesyl protein transferase (FPT) inhibition is an interesting and promising approach to non-cytotoxic anticancer therapy. Research in this area has resulted in several orally active compounds that are currently in clinical evaluation. This review focuses on FPT inhibitors in clinical trials and concentrates on the benzocycloheptapyridine class, with details on the discovery and development of SCH 66336, currently in Phase II clinical trials.
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: Anti-tumor Therapy; COS Assay; FPT Enzyme Assay; Farnesyl Protein Transferase Inhibition; Farnesylation; Geranlylgeranylation; Pharmacokinetic Assay (PK); Potent FPT Inhibitors; carboxymethyl transferase; farnesyl protein transferase

Document Type: Review Article

Publication date: 2001-10-01

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more